Sanofi has completed its acquisition of Dynavax Technologies Corporation for $15.50 per share in cash. The deal includes Dynavax's hepatitis B vaccine HEPLISAV-B, a shingles vaccine candidate in phase 1/2 studies, and additional vaccine pipeline projects. The acquisition strengthens Sanofi's adult immunization portfolio by combining Dynavax's vaccines with Sanofi's global commercial reach and development capabilities. Dynavax shares ceased trading on NASDAQ on February 10, 2026.

Sanofi has completed its acquisition of Dynavax Technologies Corporation for $15.50 per share. The deal includes Dynavax's hepatitis B vaccine HEPLISAV-B, a shingles vaccine candidate (Z-1018) in Phase 1/2 trials, and other vaccine development projects. The acquisition strengthens Sanofi's position in adult vaccination with access to Dynavax's commercial reach and development capabilities. Dynavax shares will cease trading on NASDAQ effective February 10, 2026.

David Novack, President & COO of Dynavax Technologies, exercised and sold 114,000 shares for approximately $1.8 million on January 15, 2026, netting about $680,000 after costs. The sale comes following Dynavax's announcement of a $2.2 billion acquisition by French pharmaceutical giant Sanofi at $15.50 per share, representing a 40% premium to December closing prices.

Class action law firm Monteverde & Associates PC is investigating four merger and acquisition transactions: Dynavax Technologies' sale to Sanofi ($15.50/share), FONAR Corporation's sale to affiliates of its CEO ($19.00-$6.34/share), DigitalBridge Group's sale to SoftBank ($16.00/share), and ON24's sale to Cvent Atlanta ($8.10/share). The firm is seeking shareholders to determine if the proposed deal terms are fair.

Monteverde & Associates PC, a securities class action firm, has announced an investigation into Dynavax Technologies Corporation's proposed acquisition by Sanofi. Under the deal terms, Dynavax shareholders are expected to receive $15.50 per share in cash. The firm is examining whether the transaction represents a fair deal for shareholders.

U.S. stock futures declined on Friday following Wednesday's gains, with major indices showing modest losses. Key movers included Nvidia rising on a licensing agreement with Groq, Dynavax surging 38% on Sanofi acquisition news, Sobr Safe dropping 16% after announcing a private placement, and Biohaven plummeting 14% after a failed clinical trial. Economist Justin Wolfers cautioned that U.S. market gains are lagging global markets significantly.

U.S. stock indices hover near record highs on Christmas Eve with the S&P 500 up 0.1% and year-to-date gains of 17.5%. Precious metals surge with gold breaking above $4,500/oz (up 70% YTD) and silver up 150%. The market shows mixed tech performance with AI leaders like Nvidia and Alphabet driving gains, while Intel faces pressure after Nvidia halts testing of its 18A process. Strong Q3 GDP growth of 4.3% and falling jobless claims support the bull case, though consumer confidence remains weak. The market is in late-cycle territory with valuations rich and stock selection critical.

Dynavax Technologies shares surged 38.19% on Wednesday following Sanofi's announcement to acquire the biopharmaceutical company for $15.50 per share in cash, representing approximately $2.2 billion in total equity value. The offer price reflects a 39% premium over Dynavax's closing price on Dec. 23. The acquisition includes HEPLISAV-B, an adult hepatitis B vaccine, and is subject to regulatory approvals including Hart-Scott-Rodino antitrust review.

Dynavax Technologies stock surged 38.19% after French pharmaceutical giant Sanofi announced an all-cash tender offer to acquire the biotech company for $15.50 per share, valuing it at approximately $2.2 billion. The deal represents a 39% premium to Dynavax's previous closing price and combines Dynavax's hepatitis B and shingles vaccines with Sanofi's global distribution network and development expertise.

Sanofi agreed to acquire Dynavax Technologies for $15.50 per share in cash, valuing the deal at approximately $2.2 billion. The acquisition strengthens Sanofi's adult immunization portfolio by adding Dynavax's differentiated hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate in development. The deal is expected to close in Q1 2026 and will not impact Sanofi's 2025 financial guidance. Additionally, Sanofi received a complete response letter from the FDA for its tolebrutinib multiple sclerosis drug, delaying approval beyond the December 28 target date.

Dynavax reported strong Q3 2025 financial results, with HEPLISAV-B vaccine revenue increasing 13% to $90 million. The company entered an exclusive license agreement with Vaxart for an oral COVID-19 vaccine and authorized a new $100 million share repurchase program.

Dynavax Technologies has entered an exclusive worldwide license agreement with Vaxart to develop and commercialize an oral COVID-19 vaccine candidate, paying $25 million upfront and investing $5 million in equity, with potential future milestone payments.